DGAP-News: Dermapharm Holding SE: Most successful business year in the company's history - Adjusted Group EBITDA at the upper end of the outlook
Dermapharm's broadly positioned product portfolio and its deep in-house value creation had a particularly positive effect on the successful business development in 2021.
- Dermapharm's broadly positioned product portfolio and its deep in-house value creation had a particularly positive effect on the successful business development in 2021.
- Group revenue increased by 19% to EUR 943 million in the 2021 financial year (previous year: EUR 794 million).
- Compared to the 2020 financial year, the adjusted Group EBITDA margin increased by 11.9 percentage points to 37.2% (previous year: 25.3%).
- Dermapharm will announce the final audited figures for the 2021 financial year with the full 2021 annual report on 12 April 2022.